Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25-hydroxycholecalciferol on bone mineralization  by Fournier, Albert et al.
Kidney International, Vol. 15 (1979), pp. /96 —204
Comparison of la-hydroxycholecalciferol and 25-hydroxy-
cholecalciferol in the treatment of renal osteodystrophy:
Greater effect of 25-hydroxycholecalciferol
on bone mineralization
ALBERT FOURNIER, PHILIPPE BORDIER, JEAN GUERIS, JEAN Luc SEBERT, PIERRE MARIE,
CHRISTINE FERRIERE, JEANINE BEDROSSIAN, AND HECTOR F. DELUCA
Service de Néphrologie et Clinique IVlédicale B, Centre Hospitalier Universitaire d'Amiens; André Lichwitz Research
Unit of the Institut National de Ia Sante et de la Recherche Tvlédicale (Hôpital Lariboisière), Clinique Médicale
Néphrologique, Hópital Broussias, Paris, and Department of Biochemistry, College of Agricultural and Life Science,
University of Wisconsin, Madison, Wisconsin
Comparison of la-hydroxycholecalciferol and 25-hydroxy-
cholecalciferol in the treatment of renal osteodystrophy: Greater
effect of 25-hydroxycholecalciferol on bone mineralization. A com-
parison was made of the biochemical and osseous effects of in-
OH vitamin D3 and 25-OH vitamin D3 in uremic men on chronic
hemodialysis. Two groups of patients dialyzed in the same center
were matched for their plasma concentrations of calcium (Pca),
phosphate (P0), immunoreactive parathyroid hormone (PIPTH),
25-OH vitamin D (P2Hfl), their serum alkaline phosphatase
(Alk. Pase), and their degree of osteomalacia as assessed on
bone histomorphometry. The first group received la-OH-D3 for
2 to 9 months at a mean daily dosage of 1 to 2 zg, and the second
group received 25-OH-D3 for ito 6 months at a mean daily dos-
age of 50 to 100 rig. The la-OH-D3 therapy was more effective
than the 25-OH-D3 therapy was in increasing the P( X P0 prod-
uct, in decreasing the serum Alk. Pase and the percent of osteo-
blastic surface (OB). On the other hand, 25-OH-D3 therapy ini-
tially increased bone formation and was more effective than was
the la-OH-D3 in increasing the mineralization front (MF). In one
patient, in which the MF did not increase after 9 months of
la-OH-D3, it increased from 34.0 to 44.6% after addition of 25-OH-
D3. Increased serum calcium occurred earlier with la-OH-D
than it did with 25-OH-D3 (2 vs. 8 weeks), and reversal of hyper-
calcemia was more rapid after withholding treatment with la-
OH-D3 than it was with 25-OH-D3 (1 vs. 4 weeks). It is concluded
that (1) large dosages of 25-OH-D3, rather than "physiologic" dos-
ages of la-OH-D3, induce more effectively bone mineralization
in spite of a smaller increase of the P. x Pm), product and may
be therefore a better treatment for a renal osteomalacia; (2) the
more rapid reversal of hypercalcemia induced by la-OH-D3,
however, makes the use of this tatter less hazardous than that of
25-OH-D3.
Comparison du la-hydroxycholécalciférol et du 25-hydroxy-
cholécalciférol dans le traitement de l'ostéodystrophie rénale: Ef-
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ficacité supérieure de 25-hydroxycholécatciférol sur Ia minéralisa-
tion de l'os. On a compare les effets osseux et biochimiques de Ia
la-OH-vitamine D3 et de Ia la-25-OH vitamine D3 sur deux
groupes de matades uremiques en hémodialyse chronique. Les
deux groupes étaient dialyses dans le méme centre et étaient
comparables au depart en ce qui concerne leurs concentrations
plasmatiques de calcium (Pea), de phosphore (P0) d'hormone
parathyroidienne immunoréactive (PIPTH), de 25-OH vitamine D
(P2oHD,) teurs phosphatases alcalines sériques et leur degré
d'ostéomalacie appréciée par histomorphométrie. Le premier
groupe a recu de Ia la-OH-D3 pendant 2 to 9 mois a Ia dose
journalière moyenne de 1 a 2 rg et le second groupe a recu de la
25-OH-D3 pendant 1 a 6 mois ?t Ia dose journalière moyenne de
50 a 100 g. La la-OH-D3 a été plus efficace que Ia 25-OH-D
dans l'augmentation du produit phosphocalcique, Ia diminution
des phosphatases alcalines et de Ia surface ostëoblastique. A
I'opposé Ia 25-OH-D3 entraina une augmentation initiale de la
formation osseuse et a été plus efficace que Ia la-OH-D3 dans
l'augmentation du front de minéralisation (FM). Chez un mal-
ade, le FM qui n'avait pas augmenté aprés 9 mois de la-OH-D3,
s'accrut de 34,0% a 44,6% après addition de 25-OH-D3.
L'augmentation de Ia calcémie est survenue plus rapidement
avec la la-OH-D3 qu'avec la 25-OH-D3 (2 semaines contre 8 se-
maines) et Ia correction de l'hypercalcemie a éte plus rapide
après l'arrêt de Ia la-OH-D3 qu'après arrét de la 25-OH-D3 (I se-
maine contre 4 semaines). En conclusion (1) de fortes doses de
25-OH-D3 sont plus efficaces que des doses physiologiques" de
la-OH-D3 pour augmenter la minéralisation osseuse en dépit
d'une moindre augmentation du produit phosphocalcique et
pourraient ainsi représenter un meilleur traitement de
l'ostéomalacie rénale; (2) la correction plus rapide de
l'hypercaicemie induite par la la-OH-D3 rend cependant l'usage
de cette dernière moms dangereux que celui de Ia 25-OI-T-D3.
In patients on chronic hemodialysis, radiologic
renal osteodystrophy has become less frequent [1,
2] due to a better control of calcium and phosphate
homeostasis by means of phosphate binders, oral
calcium supplements, high dialysate calcium, and
more frequent dialysis with deionized water. Com-
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plete reversal of the histologic lesions of osteitis
fibrosa or osteomalacia, or both, has rarely been
achieved, however [2—4]. Therefore, administration
of vitamin D has been used in combination with the
above measures. Variable results have been report-
ed either with parent vitamin D [5-7] and its hepatic
metabolite 25-hydroxycholecalciferol (25-OH-D3)
[4, 8—101, or with its hormonal metabolite la,25-hy-
droxycholecalciferol (la,25(OH)2-D3) [11—15], or its
analogue, 1 a-hydroxycholecalciferol (1c-OH-D3)
[16—24]. Surprisingly, the effect of la,25(OH)2D3
and of la-OH-D3 on renal osteomalacia has not
been consistently seen even with long-term studies,
whereas reduction of increased levels of plasma im-
munoreactive parathyroid hormone (iPTH) and re-
versal of osteitis fibrosa have been usual except
in cases of autonomous hyperparathyroidism [14,
23, 24]. This lack of effect of la,25(OH)2D3 in some
cases of renal osteomalacia unrelated to phosphate
depletion [14], together with some observations of
normal osteoid volume and mineralization front in
anephric patients [3], with complete absence of
la,25(OH)2D3 [25, 26], suggests that la,25(OH)2D3
may not be the metabolite solely responsible for
mineralization of the osteoid tissue. This hypothesis
is further supported by the recent study of Bordier
et a! [27] on the comparative effectiveness of 25-
OH-D3, la,25(OH)2D3, and 24, 25(OH)2D3 in adult
vitamin-D-deficient man. This study showed that
25-OH-D3 in large doses was more effective than
were its two metabolites in remineralizing osteoid
tissue and that only a combined treatment of
la,25(OH)2D3 and 24, 25(OH)2D3 led to the return
of the mineralization front to normal. This led us to
compare treatment of renal osteomalacia with large
doses of 25-OH-D3 or with "physiologic" doses of
la-OH-D3.
Methods
la-OH-D3 protocol. Four uremic patients on
chronic hemodialysis (age range, 27 to 50 years)
were given 4 jsg of 1a-OH-D at each dialysis, three
times per week, during 8 to 9 weeks. In one of these
patients, la-OH-D3 was given again, after 2 months
of discontinuation, at each dialysis at a dosage of 4
pg for 2 months and then at 2 sg for 5 months.
Aluminum hydroxide was given at a constant dos-
age of 3 to 9 glday throughout the study.
25-OH-D3 protocol. 25-OH-D3 was given to six
uremic patients on chronic hemodialysis (age range,
28 to 56 years). Five of them received 200 g at
each dialysis, three times per week, for 1 to 4
months. The last patient received only 100 jig of 25-
OH-D3 at each dialysis, three times a week, for 6
months. Aluminum hydroxide was given at a con-
stant dose of 0 to 6 g/day throughout the study. A
combination of 1a-OH-D and 25-OH-D3 was given
to the patient who previously had received la-OH-
D3 for 9 months. At each dialysis, he at first re-
ceived 2 jig of la-OH-D3 and 100 jig of 25-OH-D3
for 1 month, and then he received 1 jig of la-OH-D3
and 50 jig of 25-OH-D3 for 5 months.
Dialysis technique and other therapeutic mea-
sures. The patients were dialyzed for 6 hours, three
times a week, with a 1-rn2 cuprophane dialyzer and
a dialysate containing 7.0 mg/dl of calcium and 1.9
mg/dl of magnesium after preparation with softened
water. The diet of each patient had approximately
80 g of protein, 1.2 g of phosphorus, and I g of cal-
cium. No patient received previously vitamin D or
oral calcium supplement. None of the patients were
on anticonvulsant therapy.
Blood samples were taken before the first dialysis
of the week throughout the vitamin-D therapy and
also 1 month before and after. Plasma calcium (Pca)
and phosphate (P04) were measured by autoanalyz-
er. Plasma iPTH (P1) was determined every 2
weeks with a modification of the method of Arnaud
Tsao, and Littledike [28, 29] and with the GP1 M
antibody, which recognizes the C terminal region of
the molecule. It is expressed in nanograms of pro-
tein of parathyroid adenoma culture medium per
milliliter (normal range, 4 to 8 ng). All samples of
each patient were measured at the end of the study
in the same assay. The intraassay variability was
6%, and that of the interassay was 14%.
Plasma levels of 25-OH-D were measured in the
four patients before their treatment with la-OH-D3
and in four out of the six patients before and at the
end of their 25-OH-D3 treatment. The competitive
protein-binding assay of Ferriere, Gueris, and Mi-
ravet [30], derived from that of Belsey, DeLuca,
and Potts, Jr. [31] was used. This assay recog-
nizes not only 25-OH-D3 but also 25-OH-D2 and
24, 25(OH)2D [32]. The normal mean SD is 14.3
4.2 nglml.
Transilial bone biopsies were performed as pre-
viously described [33] in all patients, with their in-
formed consent, the first one before treatment and
the other at the end of the ito 6 months of therapy.
In one patient, four bone biopsies were taken: the
first one before la-OH-D3, the second one after 2
months of la-OH-D3, the third one after 9 months
of la-OH-D3, the fourth after 6 months of a combi-
nation of la-OH-D3 and 25-OH-D3. Serial undecal-
cified sections, 5- to 6-ji thick, were obtained and
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Table 1. Comparison of the initial status of the two groups4
Difference
la-OH-D3 (N = 4) 25-OH-D.3 (N = 6) (Wilcoxon)
Dialysis duration, months 7 to 24 1 to 15 NS
Anephric state incidence 1 2 NS
Durationof anephric state, months 12 6 to 11 NS
Clinical or radiologic symptoms 0 0 NS
Aluminum hydroxide, g/day 3 to 9 0 to 6 NS
Pca, mg/lOOml 8.6 to 10.1 8.8 to 10.2 NS
Ppo,mg/l00ml 3.5 to 6.5 4.0 to 6.1 NS
PiPTH, ng/ml 33 to 46 23 to 144 NS
Serum Alk. Pase, King Armstrong U 6 to 45 6 to 16 NS
P250HD, nglml 1.8 to 10.8 1.3 to 42.0 NS
Osteoblastic surface,
%total cancellous bone surface 5.7 to 21.0 4.1 to 15.6 NS
Osteoid volume,
%total cancellous bone tissue 5.8 to 26.3 3.7 to 15.0 NS
Osteoid surface,
% total cancellous bone surface 15 to 57 11 to 70 NS
Mineralization front,
%total osteoid surface 14 to 33 10.7 to 21.9 NS
Osteoclast count per mm2 0.6 to 1.4 0.08 to 0.96 0.05
Osteoclastic resorption surface,
% total cancellous bone surface 1.2 to 2.7 0.4 to 2.4 NS
Abbreviations used are: P, plasma concentration of; Ca, calcium; P04, phosphate; iPTH, immunoreactive parathyroid hormone; 25-
OH-D, 25-hydroxycholecalciferol; 5, serum concentration of; Alk. Pase, alkaline phosphatase.
stained with Toluidine blue. The following parame-
ters were measured (normal means SD are given
in parentheses): osteoclast count, expressed in
number per square millimeter of bone section (0.37
0.07 mm2); osteoclastic resorption surface, ex-
pressed in percent of total cancellous bone surface
(0.48 0.2%); osteoblastic surface, that is, the
osteoid surface covered with an active osteoblast
layer, expressed in percent of the total cancellous
bone surface (4.9 1.4%); osteoid volume, ex-
pressed in percent of the volume of cancellous bone
tissue (4.1 1.0%); osteoid surface, expressed in
percent of the total cancellous bone surface (14.8
3.0%); mineralization front labeled by methylchlor-
tetracycline, expressed in percent of the osteoid
surface (63.3 4.5%). The methylchlortetracycline
was given 2 days before the biopsy was performed.
Each measurement was made on ten sections ran-
domly chosen from the core of the biopsy speci-
men, and a mean value was obtained, with the intra-
biopsy variation expressed as the SEM. This permit-
ted individual assessment of the significance of the
changes obtained during the course of treatment.
Statistical methods. Comparison of groups was
made using the nonparametric test of Wilcoxon for
nonpaired data. The theoretical advantage of the
Wilcoxon test is that it does not imply a normal dis-
tribution as does Student's t test. Therefore, when
it is used, range of values and not means have been
tabulated [34]. Comparison of paired data was made
with Student's paired t test, because the paired Wil-
coxon test requires at least six paired data, and this
number was not reached in the la-OH-D3 group.
The regression calculations were made using a pro-
grammed computer.
Results
Comparison of the initial status of the two thera-
peutic groups. Table 1 shows that there was no sig-
nificant difference between the two groups initially
as regards the dialysis duration, the incidence and
duration of the anephric state, the clinical or radio-
logic symptoms, the dose of aluminum hydroxide,
Pca, P04, PiPTH, and PZ0H..D, the serum alkaline
phosphatase (SAlk. Pase), osteoblastic surface, osteoid
volume, osteoid surface, and mineralization front.
The mineralization front was below the lower limit
of normal (<50%) in all cases, whereas the osteoid
volume was above upper limit of normal (9%) in two
out of the three patients of the la-OH-D3 group and
in four out of the six patients treated with 25-OH-
D3. Thus, both groups were comparable as regards
the severity of osteomalacia and their vitamin-D
status. In spite of comparable PIPTH levels, the
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Table 2. Comparison of the biological effects of the two vitamin D sterolsa
osteoclast count was higher (P = 0.05) in the liz-
OH-D3 group, but no significant difference was
found in the active resorption surface.
Treatment duration. The duration of treatment
was comparable: from 2 to 9 months in the la-OH-
D3-treated group and 1 to 6 months in the 25-OH-D3-
treated group. Although no plasma concentration of
1 ,25(OH)2D3 was available to assess the compliance
of the patients to the la-OH-D3 administration,
measurements of P25_OHD showed that 25-OH-D3
was effectively taken since the concentrations in-
creased from an initial range of 1.3 to 42.0 ng/ml
to 25 to 302 ng/ml.
Comparison of the biochemical and histologic ef-
fects of Icx-OH-D3 with those of 25-OH-D3. Table 2
describes the range and significance of the changes
produced by the two vitamin D compounds. It also
illustrates the significance of the difference in the
responses induced by the two sterols. Both com-
pounds equally increased PCa. With 1aOHD3, Pp04
increased in three patients (that is, in four therapeu-
tic periods) and decreased in one patient, whereas
with 25-OH-D3 it increased in three patients and de-
creased in three. The difference between the two
groups as regards the hyperphosphatemic effect
was not significant. The Pca x P04 product was in-
creased more with lct-OH-D3 than it was with
25-OH-D3 (P = 0.05). PIPTH was decreased equally
(—9% to —70%) with the treatments, but remained
above normal in all patients. With la-OH-D3,
SAlk. Pase decreased in three patients and increased
in two, whereas with 25-OH-D3 it increased in four
patients and decreased in one. The difference in re-
sponse of alkaline phosphatase to the two com-
pounds was significant (P < 0.05).
Osteoblastic surface showed changes parallel to
those of SALk. Pase with la-OH-D3, it decreased in
three patients and did not change in two. With
25-OH-D3, osteoblastic surface increased signifi-
cantly in four patients, decreased in one patient,
and did not change in another one. The difference
between the two treatments was significant (P <
0.05).
Osteoid volume did not change significantly in ei-
ther of the two groups. When individual patients
treated with Ia-OH-D3 were considered, osteoid
volume (which for technical reason was not eval-
uated in one patient), decreased in two patients and
three therapeutic periods, but did not change in an-
other one with a normal initial value. With 25-OH-
D3, osteoid volume decreased in three patients, did
not change in two others, and increased in another
one, so that after treatment it remained elevated in
two patients. No significant difference between the
two groups was observed. Similarly, osteoid sur-
face did not change significantly with either drug.
Mineralization front increased significantly in two
patients but did not change in two therapeutic peri-
ods of 2 months with la-OH-D3. Therapy with lct-
OH-D3 for 7 additional months in one patient did
Changes with la-OH-D3 (N = 5)b Changes with 25-OH-D (N = 6)' Difference1-OH-D vs. 25-OH-D
(P, nonpairedSignificancec Significance
Range (paired test) Range (paired test) Wilcoxon test)
P,mg/100ml + 0.5 to + 1.8 <0.05(7) + 0.2 to + 1.7 <0.05(7) NS
Ppo, mg/lOOm! — 1.3 to + 2.5 NS(47,1\) — 1.5 to + 2.2 NS(3/,3\) NS
Pca X P0 — 4.2 to + 28.7 <0.05(7) —12.8 to 20.2 NS(37,3\) 0.05
PIpTH,%ofcontrolvalue — 9 to — 70 <0.05(\) —23 to — 70 <0.05(\) NS
Alk. Pase,KingAr,nstrong U —30 to + 5 NS(3\,27) —13 to + 16 <0.05(7) <0.05
Osteoblastic surface,
%cancellous bone surface —11.5 to + 0.5 NS(3\,2) — 5.1 to + 9.8 <0.05(7) <0.05
Osteoid volume,
% total cancellous bone tissue —13 to + 1.1 N5(3\ ,1s-) — 8.2 to 7 NS(3\ ,2, I \) NS
Osteoid surface,
%totalcancel!ousbonesurface 11 to + 4 NS(3\,2-*) — 6 to + 6 NS(5-,17) NS
Mineralization front,
%osteoid surface 0 to + 7 <0.05(27.3*) + 9 to + 22 <0.05(67) <0.05
Osteoclast count per mm2 —11 to + 0.2 NS(4\,1) — 0.5 to + 0.5 NS(2\,3-*,17) NS
Osteoclastic resorption — 1.8 to + 0.4 NS(3\,2-) — 1 to + 0.6 NS(2\,3,17) NS
See Table 1 for abbreviations used.
One patient is considered with two therapeutic periods.
Group or individual variations are given in parentheses: 7, increase; \, decrease; -*, no change.
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not induce any increase in mineralization front (Fig.
1). With 25-OH-D3, mineralization front increased
significantly in the six patients, so that the increase
with 25-OH-D3 was significantly greater than it was
with la-OH-D3. This greater effect is further illus-
trated by the significant increase of mineralization
front from 34% to 44.6% observed in the patient of
Fig. 1, 6 months after addition of 25-OH-D3 at low
dosages (50 cg and then 25 tg/day), whereas icr-
OH-D3 was decreased to 1 cg and then to 0.5 jig!
day. This increase in mineralization front was asso-
ciated with a small decrease of the calcium phos-
phate product from 54.4 to 51.5.
Osteoclast count did not change significantly, ei-
ther with la-OH-D3 or with 25-OH-D3. When the
patients treated with lcr-OH-D3 were considered in-
60 dividually, osteoclast count, which was initially ele
vated in the four patients, decreased in three pa
5.0 tients (that is, after four therapeutic periods) ant00, .did not change in one patient. With 25-OH-D3
4.0 osteoclast count decreased in two patients with mi
tial increased surface, did not change in three pa
0 tients with initial normal count, and increased it
one patient with initial normal count. The differenct
40 between the two groups was not significant.Osteoclastic resorption surface did not chang
significantly either with la-OH-D3 or with 25-OH
60 D3. When the individual patients were considered
osteoclastic resorption surface, which was initiall3
40 ci increased in all four patients treated with la-OH-D:
decreased in two patients (that is, after three thera
20 peutic periods) and did not change in two others, s
20 that after treatment, it remained elevated in two pa
10 tients. With 25-OH-D3, it decreased in two patientk with initial increased surface, did not change it
Ott
0 three others with initial normal surface, and in
creased in another one with initial normal surface
The difference between the two groups was not sig
nificant.
• 25-OH-03 A lca-OH--D3
Patient 4 with lca-OH-D3
o Patient 4 with addition of 25-OH-D3 to la-OH-D3
Fig. 2. Regression of the changes in calcifi cation front versus th
changes in PCA x Patients treated with la-OH-D3 are de
noted by triangles (A), and patients treated with 25-OH-D3, b
circles (S). A horizontal line was drawn at 8% of calcificatior
front increase to show that all patients treated with 25-OH-D3 art
above this line, whereas all patients treated with 1cs-OH-D art
below it. N = 12 refers to ten patients, one patient being consid
ered three times: twice while on lis-OH-D3 alone ® and onct
when 25-OH-Da was added to lu-OH-D3 0
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Fig. 1. Variations of the different biochemical and histomorpho-
metric parameters in the patient who was evaluated once before
any treatment, twice while on Ici-OH-D3 alone (after 2 and 9
months), and again after 6 additional months of a combination
of lu-OH-D3 and 25-OH-D3. The hatched area represents the
limits of normal for the parameters indicated along the vertical
axis, on which the hatched area is connected. The closed circles
represent the parameters of the left vertical axis (Pca), and the
open circles represent the parameters of the right vertical axis.
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Pc X Pp4
r =
—0.63
N = 12
P < 0.05
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Regression studies. Changes in PIPTH showed no
significant correlation to PCa changes nor to changes
of P04 in either group. A significant positive corre-
lation was observed between the changes in PIPTH
and those observed in osteoclast count (r = +0.88,
N = 5, P < 0.05) or in the osteoclastic resorption
surface (r = 0.80, N = 5, P = 0.05) in the la-OH-
D3-treated group but not in the group treated with
25-OH-D3. No significant correlation was found be-
tween the changes of the mineralization front and
the changes of the calcium phosphate product when
the two groups were considered separately, but a
significant negative one was found when the groups
were considered together (r =
—0.63, N = 12, P <
0.05) (Fig. 2). This latter figure shows furthermore
that all patients treated with 25-OH-D3 have an in-
crease in their mineralization front greater than 8%,
whereas those treated with la-OH-D3 have an in-
crease in their mineralization front smaller than 8%.
On the other hand, the PCa X P04 product increase
is greater than 20 in all patients treated with la-OH-
D3 except one and is equal or below 20 in all pa-
tients treated with 25-OH-D3.
Longitudinal survey of the hypercalcemic effect.
Figure 3 shows the mean weekly variations Of Pca in
the patients receiving 2 tg/day of la-OH-D3 or 100
gIday of 25-OH-D3. After starting the treatment, a
significant increase was noted (greater than 2 SEM of
pretreatment values) after 2 weeks with la-OH-D3
and 8 weeks with 25-OH-D3. When the drug was
discontinued, mean PCa returned to pretreatment
levels within a week with la-OH-D3, but not before
4 weeks with 25-OH-D3. In the patient taking 50 .tg
of 25-OH-D3 daily, PCa increased significantly only
after 2 months, and no hypercalcemia was observed
after 6 months. In the patient treated for 9 months
with la-OH-D3, the initial dosage of 2 pg/day had to
be reduced by half after 4 months of treatment to
prevent recurrence of hypercalcemia.
Discussion
The available results indicate that at the dosages
used both vitamin D compounds are equally ca-
pable of raising serum calcium, even in anephric pa-
tients. la-OH-D3 appears 50 times as effective as
25-OH-D3 in this regard. Moreover, this calcemic
effect develops more quickly with la-OH-D3 than it
does with 25-OH-D3, and following cessation of
treatment, hypercalcemia regresses much earlier in
the lct-OH-D3-treated group. The hypercalcemic ef-
fect of both these vitamin D sterols is of shorter du-
ration than it is with either vitamin D2 or D3, a
marked therapeutic advantage.
Drug administration Drug discontinuation
weeks weeks
0 2 4 8 12 16 240 —2 —4 —6 —8
1c-OH-D3
rIW
Evaluation of the effect of vitamin D on P04 in
patients on chronic hemodialysis can be difficult be-
cause predialysis Pp04 mainly depend on diet and
patient's adherence to the prescribed aluminum hy-
droxide therapy. Furthermore, phosphate removal
by dialysis is mainly dependent on dialysis duration
and frequency. Therefore, to compare the effect of
the two vitamin D sterols on predialysis P04, we
selected the patients for whom dialysis duration
was kept constant and for whom the dosage of the
prescribed aluminum hydroxide was not changed.
In these conditions, it appears that lct-OH-D3 tend-
ed to have a greater hyperphosphatemic effect than
25-OH-D3 did, although the difference was not sta-
tistically significant. The PCa x P04 product showed
a greater increase with la-OH-D3 than it did with
25-OH-D3.
The two treatments were equally effective in re-
ducing P!PTH. A significant positive correlation be-
tween the changes of PIpTU and those of osteoclast
count or active resorption surface was observed on-
ly in the la-OH-D3 group. This difference, how-
ever, does not permit the conclusion that la-OH-D3
would be more appropriate than 25-OH-D3 would
be to treat osteitis fibrosa, as the lack of correlation
found in the 25-OH-D3-treated group may be ex-
plained by the fact that the initial values of osteo-
clast count and osteoclastic resorption surface were
in the normal range in four out of six patients in this
group.
- 11.0
:: 10.0 _______________________
___________________
9.0 A/N 8.0
25-OH-D3
11.0
Co
1100 *AMA/
8.0
Fig. 3. Effect of lcs-OH-D3 and 25-OH-D3 on plasma calcium
(P4). Mean Pca with la-OH-D3 at 2 p.glday is represented by
closed triangle (A). Mean Pa with 25-OH-D at 100 1sglday is
represented by closed circle (. Pca of the patient treated with
50 g/day is represented by open circle (0). The hatched areas
represents the mean 2 SEM of the control values.
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Osteoblastic surface and SAlk Pase increased with
25-OH-D.1 and decreased with lcx-OH-D3. In nutri-
tional osteomalacia, this initial increase of the
osteoblastic surface was also observed with 25-OH-
D3 but not with la,25(OH)2D3, la-OH-D3, nor with
24,25(OH)2D3. This led to the suggestion that 25-
OH-D3 itself could stimulate the osteoblasts either
directly or indirectly through the increase of P04 in-
duced by 25-OH-D3 in vitamin-D-deficient nonure-
mic man [271. Since, in our patients, the increase in
their osteoblastic surface was observed without in-
crease in P04, we suggest that 25-OH-D3 may have
a direct stimulating effect on the osteoblasts. This
increase in the osteoblastic surface and SAlk Pase
with 25-OH-Da seems transient, however, since it is
not observed in the patient treated for 6 months
with 25-OH-D3 alone nor in the patient of Fig. 1, 6
months after addition of 25-OH-D3.
Mineralization of the osteoid tissue, as assessed
by the increase in the mineralization front, appears
to be more effectively produced by 25-OH-D3 than
it is by la-OH-D3, whereas the concomitant in-
crease in the Pca x P04 product is smaller. This
greater effect of 25-OH-D3 on the mineralization
front cannot be explained by a longer duration of
treatment or by initial lower values of the mineral-
ization front or by initial lower values of P25_OH_D.
The greater effect of 25-OH--D3 on mineralization can
neither be explained by smaller phosphate depletion
nor by smaller aluminum intoxication. These last
factors have been pointed out because lack of re-
sponsiveness of osteomalacia to la,25-OH-D3 or
la-OH-D3 has been attributed to phosphate deple-
tion [23] and to intoxication by aluminum in the wa-
ter used for the dialysate preparation [35], or to
both. In our patients, the initial P04 was com-
parable in both groups, and the exposure to alumi-
num was also comparable since all were dialyzed
with the same source of softened water and were
taking comparable amounts of aluminum hydrox-
ide. The greater effect of 25-OH-D itself in increas-
ing the mineralization front is furthermore illus-
trated by the patient of Fig. 1, whose mineralization
front did not change after 9 months of la-OH-Da but
increased by 30% when small doses of 25-OH-Da
were added. This greater effect of 25-OH-D3 com-
parative to la-OH-D3, in mineralizing bone, has
been observed also in nutritional osteomalacia by
Bordier et al [27] but was associated with a greater
increase in P04 because of a greater and a more sus-
tained reabsorption of phosphate by the kidneys.
The increase of P04 was not, however, the whole
explanation of the cure of nutritional osteomalacia,
since increasing P04 by phosphate administration
alone, without vitamin D, did not increase the min-
eralization front. A direct action of vitamin D on
bone was therefore implied with a greater efficiency
for 25-OH-D3. Our data support this hypothesis,
since we found a negative correlation between the
changes in the mineralization front and the changes
of Pca x P04 product. These findings and similar
ones reported by Eastwood et al [36] suggest that
vitamin D increases the mineralization front not pri-
marily by increasing the PCa X P04 product but by a
direct action on the bone. Since deposition of cal-
cium and phosphate in the bone should lead to a
decrease in the PCa x P04 product, this explains
why the greater the mineralization front, the lower
the PCa x P04 product and why 25-OH-D3 increases
less PCa X P04 product than it does la-OH-D3. As a
matter of fact, the smaller increase of PCa X Pp04
product with 25-OH-D3 cannot be explained by a
greater suppression of osteoclastic resorption nor
by a smaller increase of renal tubular reabsorption
of calcium and phosphate, which may be presumed
to be negligible in end-stage renal failure. A smaller
increase of calcium and phosphate intestinal ab-
sorption is another possibility, but no data are avail-
able to support it.
The fact that la,25(OH)2D3 is the metabolite into
which la-OH-D3 is transformed before any meta-
bolic effect can be observed [371 and that la-OH-D3
is less effective than 25-OH-D3 is in increasing the
mineralization front, in spite of a greater increase in
PCa x product, suggests that la,25(OH)2D3
may not be the specific metabolite for bone mineral-
ization. It can be argued, however, that because of
the short half-life of la,25(OH)2D3 (less than 24
hours according to Holick et a! [37]), administration
of 4 g of la-OH-D3 3 times per week would not
reproduce the physiologic variations of plasma
la,25(OH)D3 which is secreted at low but constant
rate, whereas pharmacologic dosages of 25-OH-D3
would induce, at least in nonanephric men, plasma
levels of lc,25(OH)2D3 that are closer to physiologic
ones because of its longer half life (12 days accord-
ing to Hadad [38]). If this hypothesis is accepted
and our data is considered, that would imply that
la,25(OH)2D3 would promote bone mineralization
at plasma levels different from those which increase
intestinal absorption. Another possibility is that the
25-OH-D3 at the dosage used acts directly without
conversion to la,25(OH)2D3. This is supported by
the calcemic effect in anephric man. It is possible
that at low dosages, la-OH-D3 does not reach the
bone site, whereas 25-OH-D3 at large dosages
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would, thus producing the increased mineralization
front. Thus, a conclusion that 25-OH-D3, at physio-
logic dosages, is more efficient at inducing mineral-
ization front cannot be made, but it does demon-
strate that whatever the mechanism, large dosages
of 25-OH-D3 may be therapeutically superior to
small dosages of la-OH-D3 in mineralizing bone.
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